Target ALS

NeuroDex Inc. is a biotechnology company focused on developing minimally invasive diagnostics for neurodegenerative disorders. Founded in 2018 and based in Arlington, Massachusetts, the company specializes in neuron-derived exosome isolation technology, which facilitates early detection, patient stratification, and disease monitoring, particularly for Alzheimer's disease. NeuroDex's innovative platform allows for blood-based diagnostics through the isolation of cell-specific extracellular vesicles, including those derived from neurons, oligodendrocytes, and glial cells. This technology has broad applications across various neurological indications and aims to provide insights into brain health, potentially leading to the first disease-modifying treatments for Alzheimer's. Through collaborations with life sciences companies and academic institutions, NeuroDex is positioned at the forefront of research in neurodegenerative diseases.

Mabylon AG, a Swiss biotechnology company, specializes in discovering and developing therapies derived from naturally occurring human antibodies. It uses advanced B-cell screening technologies and serum antibody reactivity screens on large human populations to identify rare, disease-targeting antibodies. Mabylon's lead programs include MY006 for peanut allergy, shown to prevent anaphylaxis in mouse models, and a TDP-43 targeting antibody for ALS/FTLD, partnered with SciNeuro Pharmaceuticals.

NRG Therapeutics is a drug discovery company established in 2018, specializing in therapeutic solutions aimed at restoring mitochondrial function to address neurodegenerative diseases, including Parkinson's disease, Alzheimer's disease, and motor neuron disease. Founded by a team of professionals with extensive experience in the biotech and pharmaceutical sectors, the company focuses on developing brain-penetrant mitochondrial permeability transition pore inhibitors specifically for Parkinson's disease. NRG Therapeutics seeks to create innovative medicines that preserve mitochondrial function, thereby enabling effective treatment options for patients suffering from chronic neurodegenerative disorders.